Genelux Corporation Common Stock
Symbol: GNLX (NASDAQ)
3.95
▲ (8.22%) 0.300
Company Description:
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Key Stats
- Today's Open: $3.67
- Today's High: $3.985
- Today's Low: $3.63
- Today's Volume: 252.40K
- Yesterday Close: $3.65
- Yesterday High: $3.75
- Yesterday Low: $3.56
- Yesterday Volume: 112.02K
- Last Min Volume: 100
- Last Min High: $3.95
- Last Min Low: $3.95
- Last Min VWAP: $3.95
Company Profile
- Name: Genelux Corporation Common Stock
- Website: https://www.genelux.com
- Listed Date: 2023-01-26
- Location: WESTLAKE VILLAGE, CA
- Market Status: Active
- CIK Number: 0001231457
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $137.87M
- Round Lot: 100
- Outstanding Shares: 37.77M
- Asset Type: CS
RECENT FILINGS FOR GNLX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-03 | 4 | View |
| 2025-09-03 | 4 | View |
| 2025-09-03 | 4 | View |
| 2025-09-03 | 4 | View |
| 2025-09-03 | 8-K | View |
| 2025-08-29 | 4 | View |
| 2025-08-29 | 4 | View |
| 2025-08-29 | 4 | View |
| 2025-08-29 | 4 | View |
| 2025-08-29 | 4 | View |
| 2025-08-29 | 4 | View |
| 2025-08-29 | 4 | View |
| 2025-08-29 | 4 | View |
| 2025-08-07 | S-8 | View |
| 2025-08-07 | 10-Q | View |
| 2025-07-25 | SCHEDULE 13G/A | View |
| 2025-07-11 | ARS | View |
| 2025-07-11 | DEFA14A | View |
| 2025-07-11 | DEF 14A | View |
| 2025-07-02 | 4 | View |
Latest News on GNLX